Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

BCTXBCTX
2 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in BRIACELL THERAPEUTICS CORP

No. Citadel Advisors exited its BCTX (Briacell Therapeutics) position in Q4 2025. Its Q3 2025 13F listed 11,055 shares worth $121,605. Citadel Advisors first reported BCTX in Q3 2025 and held it in 1 quarterly 13F filing.

Final Value

$0

Final Shares

0

Total Value Change

-$121,605

Total Shares Change

-11,055

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q4
Latest
Exited
0
-100.0%
$00.0%$7.59
0
2025-Q3
New
11,055
-
$121,6050.0%$10.83
34

Other major holders of BCTX: UBS Group AG, HRT FINANCIAL LP, JANE STREET GROUP, LLC, MORGAN STANLEY

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used